Kadans enters the UK life science market by acquiring, from Imperial College ThinkSpace, the B900 building located on the Babraham Research Campus (BRC) in Cambridge, adding to its Pan-European science park portfolio.
Kadans Science Partner takes first step into Cambridge and UK life science market
The fully let property accommodates two companies (Abzena and Bicycle Therapeutics) active in the field of cancer and immunology therapeutics, forming a welcome addition to Kadans existing science partner network including tenants such as Genmab, Merus and MDxHealth.
The recently developed, high quality bio- and chemistry laboratory facility as well as BRC as a location is a valuable addition to the Kadans portfolio. Babraham Research Campus is an internationally well recognized life sciences cluster, with over 60 companies co-located with the Babraham Institute providing shared facilities and supporting programs. Kadans aims to further build on the strengths of the campus, in conjunction with campus management organization Babraham Bioscience Technologies (BBT), and deliver international connectivity, technical design capabilities, operating experience and capital to the mix.
Kadans’ portfolio comprises 20 properties across nine campus locations, serving more than 230 tenants. Currently two new science park locations and five buildings are being developed and will be added to the portfolio after completion. In addition, Kadans is actively working on securing new projects in Germany, Spain, the Netherlands and the UK.
The acquisition of the B900 building marks a first step on the Babraham Research Campus and in the UK. Kadans aspires to partner with universities and organisations across the UK and beyond to build one strong knowledge-sharing ecosystem of science parks.
Kadans was supported in this transaction by Creative Places specialist R&D real estate consultants. ThinkSpace was unrepresented. Mills & Reeve acted as legal advisors for Kadans.
The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise. World class research and business come together to promote innovation and strengthen links between academia and the commercial world.